U.S. Markets closed

How Analysts Are Rating Puma Biotechnology in July

Daniel Collins
How Analysts Are Rating Puma Biotechnology in July

The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.